Research Article

Association of Obstructive Sleep Apnea Syndrome (OSA/OSAHS) with Coronary Atherosclerosis Risk: Systematic Review and Meta-Analysis

Liwen Chen, Shujing Zou, and Jinhong Wang

Department of Respiration, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China 510630

Correspondence should be addressed to Jinhong Wang; leechy911@126.com

Received 22 June 2022; Revised 20 July 2022; Accepted 22 July 2022; Published 17 August 2022

Academic Editor: Ahmed Faeq Hussein

Copyright © 2022 Liwen Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Obstructive sleep apnea syndrome (OSA) is the most common type of sleep disorders. This study aimed to systematically review the correlation between OSA and the risk of coronary atherosclerosis.

Methods. Literature on case-control studies on the relationship between coronary heart disease (CHD) and sleep apnea syndrome was collected and collated, and the incidence of SAS in CHD and non-CHD patients was observed and compared. RevMan 5.2 analysis software and Stata12SE analysis software were used for heterogeneity test and combination analysis of the included studies. The results were expressed with odds ratio (OR), 95% confidence intervals (CI) were calculated, and publication bias and sensitivity tests were evaluated.

Results. There was a statistical difference in OSA associated with the risk of coronary atherosclerosis between the experimental group and the control group \[ OR = 1.38, 95\% \text{ CI } (1.18, 1.62), P < 0.0001, I^2 = 0\%, Z = 3.93 \]. OSA associated with vascular endothelial injury \[ OR = 3.59, 95\% \text{ CI } (3.00, 4.29), P < 0.00001, I^2 = 90\%, Z = 14.09 \]. OSA is associated with vascular oxidation emergency \[ OR = 2.19, 95\% \text{ CI } (2.05, 2.33), P < 0.00001, I^2 = 94\%, Z = 23.40 \]; OSA is associated with chronic vascular inflammation \[ OR = 1.70, 95\% \text{ CI } (1.39, 2.07), P < 0.00001, I^2 = 16\%, Z = 5.18 \]. Conclusion. The incidence of obstructive sleep apnea in patients with CHD was higher than that in non-CHD patients, and obstructive sleep apnea was a risk factor for CHD.

1. Introduction

Coronary heart disease is closely related to OSA/OSAHS [1]. At present, there are already at home and abroad, and there are many case-control studies on the relationship between coronary heart disease and SAS, but they are generally limited to small sample size and large selection bias [2–4]. Obstructive sleep apnea syndrome (OSAS) is airway obstruction that can lead to significant physiologic disturbance with numerous clinical impacts. Sleep apnea syndrome (SAS) is a potentially dangerous disease with high morbidity. According to the etiology, it can be divided into obstructive, central, mixed, and obstructive sleep apnea syndrome. OSAS is the most common. Multiple regression analysis has confirmed that SAS is a risk factor for unstable angina pectoris and myocardial infarction, but there is still a lack of large-scale clinical studies in China [5]. The occurrence of OSA is as high as 40% to 80% in patients with hypertension, coronary artery disease, heart failure, and pulmonary hypertension. Despite its high prevalence in patients with heart disease patients, OSA is often underrecognized and undertreated in cardiovascular practice.

The introduction of the 2021 American Heart Association/American Foundation of Cardiology Scientific Statement on Sleep apnea and Cardiovascular Disease has led to recognition of the impact of sleep apnea on cardiovascular disease. Early detection and timely correction of sleep apnea play an important role in the secondary prevention of coronary heart disease (coronary heart disease). Foreign epidemiological data show that SAS is a disease with high morbidity and high risk [6]. The incidence of adult sleep apnea is 4%~7%, and OSAS accounts for more than 90%,
adult male 4% and female 2%. The incidence increases with the increase of age, and the incidence of the elderly over 50 years old >6%. According to the preliminary epidemiological survey of OSAS in China, the prevalence rate is about 4% [7]. Based on the population of 1.3 billion in China, there are at least 52 million OSAS patients [8].

An increase in baseline BMI of kg/m² was associated with a 12% increased risk of coronary heart disease. Body mass index was closely correlated with apnea/hypopnea index, respiratory disorder index and oxygen saturation index, and independently correlated with apnea/hypopnea index. Apnea/hypopnea index was also an independent risk predictor of CHD death in a follow-up study [9]. The possible mechanism of sleep disorders in obese patients is as follows: the increase of body mass in obese patients affects the thorax and abdomen, reduces the compliance of chest wall, reduces the volume of lung tissue, and aggravates the mechanical load of respiratory system. As a result, the functional residual volume decreases, especially in the supine position. Obesity causes sleep apnea mainly by increasing the soft tissue around the upper respiratory tract, resulting in upper respiratory tract obstruction, resulting in apnea and insufficient ventilation, repeated awakening, and so on, resulting in repeated hypoxemia, hypercapnia, and acidic environment in the body. More patients with sleep apnea combined with coronary heart disease developed angina pectoris at night, suggesting an imbalance between myocardial oxygen supply and myocardial oxygen consumption, which may play a role through the following mechanisms.

In this study, meta-analysis was conducted on domestic and foreign clinical case-control studies on the relationship between coronary heart disease and OSA to obtain comprehensive quantitative analysis results of the relationship between coronary heart disease and OSA, so as to make up for the deficiency of single studies and provide more reliable evidence-based medical evidence.

### 2. Materials and Methods

#### 2.1. Literature Retrieval Strategy

The main retrieval words were "coronary heart disease, sleep apnea syndrome, coronary artery disease, CAD, Sleep apnea syndrome, obstructive sleep apnea syndrome." Combined with CAD and CHD, SAS and OSAHS ensure the comprehensiveness of the index. China National Knowledge Infrastructure (CNKI), CBMdisc, VIP, Wanfang, PubMed, Embase, Cochrane, and Google Scholar were searched by computer, supplemented by literature retrospective and manual retrieval methods. All literatures on the relationship between coronary heart disease and
obstructive sleep apnea syndrome were retrieved from the self-established database up to December 31, 2021 (Figure 1).

2.2. Literature Inclusion Criteria. The literature inclusion criteria were as follows: ① open and unpublished primary literature; ② the original data are complete; and ③ patients with coronary heart disease and noncoronary heart disease. The incidence of OSA was a case-control study. ④ The diagnostic criteria of coronary heart disease are the same. According to the American College of Cardiology (ACC) and the American Heart Association (AHA) coronary angiography (CAG) guidelines, CAG demonstrates ≥50% stenosis of 1 or more coronary vessels. The diagnostic criteria for OSA are the same. Apnea was defined by polysomnogram (PSG) as at least 10 s of airflow cessation from the nose and mouth. Hypopnea was defined as a 50% reduction in airflow, lasting more than 10 s, with a corresponding decrease in oxygen saturation of ≥4%.

OSA was diagnosed with sleep apnea hypopnea index (AHI) ≥5 or PSG for more than 30 recurrent episodes of apnea and hypopnea during 7 hours of sleep per night. Because some studies used AHI≥10 as SAS diagnostic criteria, we analyzed the differences according to the diagnostic criteria.

2.3. Literature Exclusion Criteria. The literature exclusion criteria are as follows: ① review literature and other nonprimary literature; ② there is no literature for extracting data; ③ studies without clear definition of diagnostic criteria for coronary heart disease and obstructive sleep apnea syndrome; and ④ repeated publication of literature.

2.4. Literature Quality Evaluation. The selected studies were case-control studies. The Newcastle-Ottawa Scale (NOS) was used to score literature quality, and independent evaluations were carried out in pairs in terms of case selection and group allocation.
control conditions, intergroup comparability, and similarity of exposure factors. Differences were discussed and resolved. If the problem is still unresolved, it will be submitted to the third party for evaluation. The full score was 9 stars, and literatures with a total score of more than 5 stars could be included in the meta-analysis (Figure 2).
2.5. Heterogeneity Test and Meta-Analysis. If the evaluation results showed no publication bias, the heterogeneity test was carried out among the studies. If there was no heterogeneity among the studies, the fixed-effect model was used for analysis. If heterogeneity exists between studies, random effects model is used to analyze. Meta-analysis was used to compare the experimental group and the control group.

### Figure 4: Meta-analysis of OSA associated with the risk of coronary atherosclerosis between two groups.

| Study or Subgroup | Experimental group | Control group | Weight | Odds Ratio M–H, Fixed, 95% CI | Odds Ratio M–H, Fixed, 95% CI | Risk of Bias |
|-------------------|-------------------|---------------|--------|-------------------------------|-------------------------------|-------------|
|                   | Events | Total | Events | Total |                          |                               |             |
| Balcan B 2019     | 69     | 99    | 72     | 104   | 8.4%                         | 1.02 [0.56, 1.86]             |             |
| Balcan B 2020     | 135    | 244   | 109    | 244   | 19.2%                        | 1.53 [1.07, 2.19]             |             |
| Celik Y 2021      | 108    | 208   | 100    | 208   | 18.9%                        | 1.17 [0.79, 1.71]             |             |
| Glantz H 2013     | 362    | 662   | 300    | 662   | 53.5%                        | 1.46 [1.17, 1.81]             |             |
| Total (95% CI)    | 1213   | 1218  | 100.0% |       | 1.38 [1.18, 1.62]            |                               |             |
| Total events      | 674    | 581   |        |       |                               |                               |             |

Heterogeneity: Chi² = 2.28, df = 3 (P = 0.52); I² = 0%
Test for overall effect: Z = 3.93 (P < 0.0001)

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias

### Figure 5: Meta-analysis of OSA associated with vascular endothelial injury between two groups.

| Study or Subgroup | Experimental group | Control group | Weight | Odds Ratio M–H, Fixed, 95% CI | Odds Ratio M–H, Fixed, 95% CI | Risk of Bias |
|-------------------|-------------------|---------------|--------|-------------------------------|-------------------------------|-------------|
|                   | Events | Total | Events | Total |                          |                               |             |
| Glantz H 2015     | 311    | 431   | 120    | 431   | 26.0%                        | 6.72 [4.95, 9.05]             |             |
| Glantz H 2017     | 145    | 244   | 95     | 95    | 30.0%                        | 2.53 [1.60, 3.99]             |             |
| Huang Z 2016      | 40     | 70    | 30     | 70    | 10.0%                        | 1.78 [0.91, 3.47]             |             |
| Lewis EF 2017     | 200    | 318   | 118    | 318   | 34.0%                        | 2.87 [2.08, 3.96]             |             |
| Total (95% CI)    | 1063   | 1063  | 100.0% |       | 3.59 [3.00, 4.29]            |                               |             |
| Total events      | 696    | 363   |        |       |                               |                               |             |

Heterogeneity: Chi² = 28.89, df = 3 (P < 0.0001); I² = 90%
Test for overall effect: Z = 14.09 (P < 0.0001)

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias

### Figure 6: Meta-analysis of OSA associated with vascular oxidation emergency between two groups.

| Study or Subgroup | Experimental group | Control group | Weight | Odds Ratio M–H, Fixed, 95% CI | Odds Ratio M–H, Fixed, 95% CI | Risk of Bias |
|-------------------|-------------------|---------------|--------|-------------------------------|-------------------------------|-------------|
|                   | Events | Total | Events | Total |                          |                               |             |
| Liu X 2014        | 32     | 40    | 26     | 40    | 0.4%                         | 2.15 [0.78, 5.92]             |             |
| McEvoy RD 2016    | 1700   | 2717  | 1037   | 2717  | 31.6%                        | 2.79 [2.50, 3.12]             |             |
| Ogihara RP 2018   | 2210   | 3874  | 3874   | 3874  | 59.0%                        | 1.76 [1.61, 1.93]             |             |
| Sánchez-de-la-Torre A 2016 | 499    | 796   | 796    | 796   | 9.1%                         | 2.82 [2.30, 3.46]             |             |
| Total (95% CI)    | 7427   | 7427  | 100.0% |       | 2.19 [2.05, 2.33]            |                               |             |
| Total events      | 4441   | 3004  |        |       |                               |                               |             |

Heterogeneity: Chi² = 47.10, df = 3 (P < 0.0001); I² = 94%
Test for overall effect: Z = 23.40 (P < 0.0001)

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias
angiography was not performed in 6 of the excluded litera-
cases, and 9 of the excluded literatures were consid-
24] after independent screening and evaluation
literatures related to coronary heart disease and obstructive
sleep apnea syndrome were retrieved, including 14 litera-
forcement using RevMan 5.2 software. The results were
fl significant (Figure 3).

Population (P): Patients meets the diagnostic criteria of
Intervention (I): Whether patients had OSA
Comparison (C): The control was whether patients in
Outcome measures (O): OSA associated with the risk of
coronary artery disease
Study design (S): Retrospective analysis

2.6. Sensitivity Analysis. Stability sensitization of the results
was observed by eliminating important studies that might

2.7. Statistical Analysis. All statistical calculations were car-
ried out using SPSS statistical software. Because Stata anal-
software can provide quantitative analysis of publication
bias, Sata12 software is used for publication bias evaluation.
If there is publication bias, the method of "Cutting and fill-
ing" is used to correct it. If it cannot be corrected, discussion
of publication bias can only be conducted. P values <0.05
were considered significant.

3. Result

3.1. Results of Literature Quality Evaluation. A total of 351
literatures related to coronary heart disease and obstructive
sleep apnea syndrome were retrieved, including 14 litera-
tures [11–24] after independent screening and evaluation
by two persons. Although 9 of the excluded literatures were
case-control studies of coronary heart disease, coronary
angioigraphy was not performed in 6 of the excluded liter-
tures, and the diagnostic criteria of obstructive sleep apnea
syndrome were not clearly indicated in 3 of the excluded
literatures. 9 control studies used AN AHI≥5 as a diagnostic
criterion for OSA, and five control studies used an AHI≥10
as a diagnostic criterion for OSA (Table 1).

3.2. OSA Associated with the Risk of Coronary Atherosclerosis. Among the 14 RCTs literatures included in
OSA associated with the risk of coronary atherosclerosis,
heterogeneity test was carried oysis for 4 included literatures,
so there was a statistical difference in OSA associated with
the risk of coronary atherosclerosis between the experimen-
tal group and the control group [OR = 1.38, 95% CI (1.18,
1.62), P < 0.00001, I² = 0%, Z = 3.93] (Figure 4).

3.3. OSA Associated with Vascular Endothelial Injury. Among the 14 RCTs literatures included in OSA associated
with vascular endothelial injury, heterogeneity test was car-
ried oysis for 4 included literatures, so there was a statistical
difference in OSA associated with vascular endothelial injury
between the experimental group and the control group
[OR = 3.59, 95% CI (3.00, 4.29), P < 0.00001, I² = 90%, Z =
14.09] (Figure 5).

3.4. OSA Associated with Vascular Oxidation Emergency. Among the 14 RCTs literatures included in OSA associated
with vascular oxidation emergency, heterogeneity test was carried oysis for 4 included literatures, so there was a statistical
difference in OSA associated with vascular oxidation emergency
between the experimental group and the control group
[OR = 2.19, 95% CI (2.05, 2.33), P < 0.00001, I² = 94%,
Z = 23.40] (Figure 6).

3.5. OSA Associated with Chronic Vascular Inflammation. Among the 14 RCTs literatures included in OSA associated
with chronic vascular inflammation, heterogeneity test was
ried oysis for 4 included literatures, so there was a statistical
difference in OSA associated with chronic vascular inflammation
between the experimental group and the control group
[OR = 1.70, 95% CI (1.39, 2.07), P < 0.00001, I² =
16%, Z = 5.18] (Figure 7).
4. Discussion

The selected studies in this study were verified to have no publication bias, and sensitivity analysis also showed that the results of this study were relatively reliable. Among all 14 studies included in this study, the 95% CI of 2 included 1, indicating that the difference was not statistically significant and could not indicate that OSA was a risk factor for coronary heart disease [26]. The OR value of 12 studies was greater than 1, and the 95% CI lower limit was greater than 1, indicating that OSA is a risk factor for coronary heart disease [27]. However, after the integration and analysis of individual studies, the OR values were all greater than 1, and the 95% CI lower limit was greater than 1, and the P values were all less than 0.05, indicating statistically significant differences [28–31]. These results indicated that after multiple studies were combined, OSA was still positively associated with the occurrence of coronary heart disease, and OSA was a risk factor for coronary heart disease [32]. Moreover, the 95% CI interval after economic cooperation and integration is significantly reduced, which makes the reliability of the sample index to estimate the overall parameters better.

Conclusion based on single research results is difficult to reflect the essence of things and may result in accidental results due to the action of a variety of factors [33]. Meta-analysis is a research method that systematically analyzes and quantitatively synthesizes the results of multiple independent studies with the same research purpose [34]. The purpose is to improve the statistical test efficiency, evaluate the inconsistencies or contradictions of research results, find the shortcomings of a single study, and process a large number of literatures, which is not limited by the number of studies [35–37]. It plays an important role in clinical diagnosis, treatment, risk assessment, preventive intervention, health service, and decision-making. Due to the small sample size of clinical case studies of OSA and CHD, this paper provides a quantitative average effect or correlation combined with multiple studies, which makes the confidence interval more convergent. The results of each study are more comprehensive and quantitative, and the conclusion is more comprehensive and reliable. OSA contributes to the occurrence of CHD through a variety of mechanisms, but the specific mechanisms have not been fully elucidated. OSA induced apnea, and chronic intermittent hypoxia and sleep structure disorders can cause a series of pathophysiological changes such as hemodynamic changes, sympathetic nervous activity increases, and vascular endothelial dysfunction, which are conducive to the occurrence of coronary heart disease [38]. The main pathological mechanism of coronary heart disease: pathophysiological changes, such as increased left ventricular load, sympathetic-parasympathetic imbalance, oxidative stress, inflammation and vascular endothelial dysfunction, promote and aggravate the occurrence and development of coronary atherosclerosis, and ultimately lead to coronary heart disease [39].

The advantage of this study was to analyze the incidence of obstructive sleep apnea in patients with CHD, which will provide solid foundation for future treatment. However, there are also shortcomings of this study: (1) In addition to OSA as the main observational factor in the included study, there are many other coronary heart disease risk factors, and it is difficult to use meta-analysis to combine correction or exclude the influence of other treatment factors; (2) meta-analysis is not an experimental study, and there may be a variety of bias; and (3) all included studies were hospital-based case-control studies. According to the NOS scale, it is impossible to evaluate the quality of all literature.

5. Conclusion

The incidence of obstructive sleep apnea in patients with CHD was higher than that in non-CHD patients, and obstructive sleep apnea was a risk factor for CHD.

Data Availability

The data used to support this study is available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

We would like to thank the reviewers who worked hard for the publication of this research.

References

[1] X. Tingting, Y. Danming, and C. Xin, “Non-surgical treatment of obstructive sleep apnea syndrome,” European Archives of Oto-Rhino-Laryngology, vol. 275, no. 2, pp. 335–346, 2018.
[2] J. J. Lee and K. M. Sundar, “Evaluation and management of adults with obstructive sleep apnea syndrome,” Lung, vol. 199, no. 2, pp. 87–101, 2021.
[3] P. Bargiota, I. Bargiota, I. Debove et al., “Sleep apnea syndrome and subthalamic stimulation in Parkinson’s disease,” Sleep Medicine, vol. 86, pp. 106–112, 2021.
[4] H. Ota, Y. Fujita, M. Yamauchi, S. Muro, H. Kimura, and S. Takasawa, “Relationship between intermittent hypoxia and type 2 diabetes in sleep apnea syndrome,” International Journal of Molecular Sciences, vol. 20, no. 19, p. 4756, 2019.
[5] R. Shobatake, H. Ota, N. Takahashi, S. Ueno, K. Sugie, and S. Takasawa, “Anorexigenic effects of intermittent hypoxia on the gut-brain axis in sleep apnea syndrome,” International Journal of Molecular Sciences, vol. 23, no. 1, p. 364, 2022.
[6] I. Nakari and K. Takadama, “Sleep apnea syndrome detection based on degree of convexity of logarithmic spectrum calculated from overnight bio-vibration data of mattress sensor,” Annual International Conference of the IEEE Engineering in Medicine and Biology Society, vol. 2021, pp. 2270–2273, 2021.
[7] O. Nikitidou, E. Daskalopoulou, A. Papagianni et al., “Sleep apnea syndrome, inflammation and oxidative stress in hemodialysis patients,” Hemodialysis International, vol. 22, no. 2, pp. 209–216, 2018.
[8] E. Soylermez, O. Ozturk, S. A. Baslo, Z. E. Balci, and D. Atakli, “Metabolic syndrome and obstructive sleep apnea syndrome
among patients with epilepsy on monotherapy,” *Epilepsy & Behavior*, vol. 111, p. 107296, 2020.

[9] F. Pistorius, P. Geisler, T. C. Wetter, and T. Crönlein, “Sleep apnea syndrome comorbid with and without restless leg syndrome: differences in insomnia specific symptoms,” *Sleep & Breathing*, vol. 24, no. 3, pp. 1167–1172, 2020.

[10] P. Edouard, D. Campo, P. Bartet et al., “Validation of the Withings sleep analyzer, an under-the-mattress device for the detection of moderate-severe sleep apnea syndrome,” *Journal of Clinical Sleep Medicine*, vol. 17, no. 6, pp. 1217–1227, 2021.

[11] R. P. Oglivie, K. Lakshminarayan, C. Iber, S. R. Patel, and P. L. Lutsey, “Joint effects of OSA and self-reported sleepiness on incident CHD and stroke,” *Sleep Medicine*, vol. 44, pp. 32–37, 2018.

[12] R. D. McEvoy, N. A. Antic, E. Heeley et al., “CPAP for prevention of cardiovascular events in obstructive sleep apnea,” *The New England Journal of Medicine*, vol. 375, no. 10, pp. 919–931, 2016.

[13] A. V. Zinchuk, J. H. Chu, J. Liang et al., “Physiological traits and adherence to sleep apnea therapy in individuals with coronary artery disease,” *American Journal of Respiratory and Critical Care Medicine*, vol. 204, no. 6, pp. 703–712, 2021.

[14] Y. Celik, E. Thunström, P. J. Strollo Jr., and Y. Peker, “Continuous positive airway pressure treatment and anxiety in adults with coronary artery disease and nonsleepy obstructive sleep apnea in the RICCADSA trial,” *Sleep Medicine*, vol. 77, pp. 96–103, 2021.

[15] H. Glantz, E. Thunström, J. Herlitz et al., “Occurrence and predictors of obstructive sleep apnea in a revascularized coronary artery disease cohort,” *Annals of the American Thoracic Society*, vol. 10, no. 4, pp. 350–356, 2013.

[16] H. Glantz, E. Thunström, M. C. Johansson et al., “Obstructive sleep apnea is independently associated with worse diastolic function in coronary artery disease,” *Sleep Medicine*, vol. 16, no. 1, pp. 160–167, 2015.

[17] B. Balcan, E. Thunström, P. J. Strollo Jr., and Y. Peker, “Continuous positive airway pressure treatment and depression in adults with coronary artery disease and nonsleepy obstructive sleep apnea. A secondary analysis of the RICCADSA trial,” *Annals of the American Thoracic Society*, vol. 16, no. 1, pp. 62–70, 2019.

[18] E. Thunström, H. Glantz, T. Yucel-Lindberg, K. Lindberg, M. Saygin, and Y. Peker, “CPAP does not reduce inflammatory biomarkers in patients with coronary artery disease and nonsleepy obstructive sleep apnea: a randomized controlled trial,” *Sleep*, vol. 40, no. 11, 2017.

[19] X. Liu, L. Feng, G. Cao et al., “Cardiac structure and function improvements in coronary artery disease combined with severe obstructive sleep apnea/hypopnea syndrome patients via noninvasive positive pressure ventilation therapy,” *Coronary Artery Disease*, vol. 25, no. 6, pp. 516–520, 2014.

[20] B. Balcan, E. Thunström, T. Yucel-Lindberg, K. Lindberg, P. Ay, and Y. Peker, “Impact of CPAP treatment on leptin and adiponectin in adults with coronary artery disease and nonsleepy obstructive sleep apnoea in the RICCADSA trial,” *Sleep Medicine*, vol. 67, pp. 7–14, 2020.

[21] E. F. Lewis, R. Wang, N. Punjabi et al., “Impact of continuous positive airway pressure and oxygen on health status in patients with coronary heart disease, cardiovascular risk factors, and obstructive sleep apnea: a heart biomarker evaluation in apnea treatment (HEARTBEAT) analysis,” *American Heart Journal*, vol. 189, pp. 59–67, 2017.

[22] Z. Huang, Z. Liu, Z. Zhao, Q. Zhao, Q. Luo, and Y. Tang, “Effects of continuous positive airway pressure on lipidemia and high-sensitivity C-reactive protein levels in non-obese patients with coronary artery disease and obstructive sleep apnoea,” *Heart, Lung & Circulation*, vol. 25, no. 6, pp. 576–583, 2016.

[23] H. Glantz, M. C. Johansson, E. Thunström et al., “Effect of CPAP on diastolic function in coronary artery disease patients with nonsleepy obstructive sleep apnea: a randomized controlled trial,” *International Journal of Cardiology*, vol. 241, pp. 12–18, 2017.

[24] A. Sánchez-de-la-Torre, J. Abad, J. Durán-Cantolla et al., “Effect of patient sex on the severity of coronary artery disease in patients with newly diagnosis of obstructive sleep apnoea admitted by an acute coronary syndrome,” *PLoS One*, vol. 11, no. 7, article e0159207, 2016.

[25] B. Kollar, P. Siarnek, A. Hluchanova et al., “The impact of sleep apnea syndrome on the altered lipid metabolism and the redox balance,” *Lipids in Health and Disease*, vol. 20, no. 1, p. 175, 2021.

[26] M. Casale and R. Vittorio, “Topical collection: sleep apnea syndrome: from the pathogenesis to the last therapies,” *European Archives of Oto-Rhino-Laryngology*, vol. 278, no. 3, p. 849, 2021.

[27] L. Ouanes-Besbes, Z. Hammouda, S. Besbes et al., “Diagnosis of sleep apnea syndrome in the intensive care unit: a case series of survivors of hypercapnic respiratory failure,” *Annals of the American Thoracic Society*, vol. 18, no. 4, pp. 727–729, 2021.

[28] A. Sugimoto, H. Shozawa, K. Mizuma, S. Hieda, and K. Ono, “Pallidal dementia with underlying sleep apnea syndrome: a case report and literature review,” *Neurological Sciences*, vol. 41, no. 7, pp. 1961–1963, 2020.

[29] V. L. Aengevaeren, A. Mosterd, S. Sharma et al., “Exercise and coronary atherosclerosis: observations, explanations, relevance, and clinical management,” *Circulation*, vol. 141, no. 16, pp. 1338–1350, 2020.

[30] M. C. Williams, D. E. Newby, and E. D. Nicol, “Coronary atherosclerosis imaging by CT to improve clinical outcomes,” *Journal of Cardiovascular Computed Tomography*, vol. 13, no. 5, pp. 281–287, 2019.

[31] S. P. Whelton, J. D. Bundy, and P. K. Whelton, “Coronary atherosclerosis across the continuum of blood pressure,” *American Journal of Hypertension*, vol. 34, no. 8, pp. 799–800, 2021.

[32] P. M. Carlucci, M. M. Purmalek, A. K. Dey et al., “Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus,” *JCI Insight.*, vol. 3, no. 8, article e99276, 2018.

[33] M. B. Mortensen, O. Dzayev, F. H. Steffensen et al., “Impact of plaque burden versus stenosis on ischemic events in patients with coronary atherosclerosis,” *Journal of the American College of Cardiology*, vol. 76, no. 24, pp. 2803–2813, 2020.

[34] A. Lin, D. Dey, D. T. L. Wong, and N. Nerlekar, “Perivascular adipose tissue and coronary atherosclerosis: from biology to imaging phenotyping,” *Current Atherosclerosis Reports*, vol. 21, no. 12, p. 47, 2019.

[35] J. C. Lee, D. G. Lyall, and Y. S. Chen, “Coronary atherosclerosis and malignancies in diabetic patients,” *Cardiology*, vol. 146, no. 6, pp. 737–738, 2021.

[36] S. Lai, “HIV and coronary atherosclerosis: research separates association from causation,” *Radiology*, vol. 299, no. 3, pp. 581–582, 2021.
[37] B. Rizzacasa, F. Amati, F. Romeo, G. Novelli, and J. L. Mehta, “Epigenetic modification in coronary atherosclerosis,” *Journal of the American College of Cardiology*, vol. 74, no. 10, pp. 1352–1365, 2019.

[38] G. Casolo, M. G. Abrignani, A. F. Amico et al., “ANMCO/SIC/GISE/ARCA/SIRM consensus document: description of coronary atherosclerosis for diagnostic, prognostic and therapeutic purposes,” *Giornale Italiano di Cardiologia*, vol. 20, no. 7, pp. 439–468, 2019.

[39] M. A. Zayed, “Immune modulation of coronary atherosclerosis with anticytokine treatment,” *Circulation. Cardiovascular Imaging*, vol. 13, no. 9, article e011451, 2020.